Clinical overview
Urinary incontinence (UI), defined by the International Continence Society as the complaint of any involuntary loss of urine, is one of the most prevalent conditions in women's health, affecting a substantial minority of adult women and a majority of the elderly and parous. It is chronically under-reported — out of embarrassment, and from the mistaken belief that leakage is an inevitable consequence of childbearing or ageing — yet it is rarely dangerous and almost always improvable. Its impact is on dignity, work, physical activity, sexual function and mental health, and the burden of containment (pads, restricted fluids, "toilet-mapping") is itself disabling.
This is an HOTS objective focused on classification, definitions and pathophysiology, because correct classification is the clinical work: the type of incontinence dictates the entire management pathway, and the commonest errors are pathophysiological mislabels — treating overflow as overactive bladder, or treating a fistula as stress incontinence. The two dominant types are stress urinary incontinence (SUI) — leakage on effort or exertion — and urgency urinary incontinence (UUI), the key storage symptom of the overactive bladder (OAB) syndrome; many women have mixed UI. Two further patterns must always be actively excluded because they are managed entirely differently: overflow incontinence from chronic retention (urinary-retention) and continuous incontinence, which should always raise the suspicion of a fistula (gynaecological-fistulas). This chapter sets out the continence mechanism, the definitions and classification, the pathophysiology of each type, and the NICE-based stepped management — reshaped in recent years by the national pause on vaginal mesh. It links to genital-prolapse (which frequently coexists) and climacteric-and-menopause (genitourinary atrophy).
Core knowledge
Definitions (ICS)
- Stress UI — involuntary leakage on effort/exertion or on sneezing/coughing.
- Urgency UI — involuntary leakage accompanied by, or immediately preceded by, urgency (a sudden compelling desire to void that is difficult to defer).
- Mixed UI — both of the above.
- Overactive bladder (OAB) syndrome — urgency, usually with frequency (≥8 voids/day) and nocturia, with (OAB-wet) or without (OAB-dry) urgency incontinence, in the absence of infection or other obvious pathology.
- Overflow incontinence — leakage from a chronically over-distended, poorly emptying bladder.
- Continuous incontinence — constant leakage, classically from a fistula or an ectopic ureter.
The continence mechanism
Figure C2.1 — Why continence fails: the pressure balance (urethral closure vs detrusor pressure), and the mechanisms of stress, urgency/OAB, overflow, mixed and continuous (fistula/ectopic ureter) incontinence.
Continence is maintained whenever urethral closure pressure exceeds intravesical (detrusor) pressure, both at rest and during rises in intra-abdominal pressure. The contributors:
- Urethral support — the anterior vaginal wall and its attachments (the pubourethral ligaments and the levator-ani "hammock", as described by DeLancey) provide a firm backboard against which the urethra is compressed when abdominal pressure rises (the pressure-transmission and integral theories). Intact support means a cough is transmitted equally to bladder and urethra, preserving the pressure gradient.
- Intrinsic sphincter — the smooth and striated urethral musculature and urethral wall tone generate the maximum urethral closure pressure (MUCP) at rest.
- Mucosal coaptation and the submucosal vascular plexus — seal the urethral lumen; both are oestrogen-dependent, which is why genitourinary atrophy worsens symptoms after the menopause (climacteric-and-menopause).
Stress urinary incontinence — pathophysiology
SUI occurs when a rise in intra-abdominal pressure overcomes urethral closure. Two mechanisms, often coexisting:
- Urethral hypermobility — loss of the supportive hammock (vaginal delivery, ageing, connective-tissue change) allows the bladder neck and proximal urethra to descend and rotate on straining, so abdominal pressure is transmitted unequally and the urethra "gives". This is the commoner mechanism.
- Intrinsic sphincter deficiency (ISD) — an intrinsically weak sphincter that cannot maintain closure pressure regardless of support (prior surgery with scarring/denervation, ageing, hypo-oestrogenism, neurological disease). ISD causes more severe leakage and is suggested by a low MUCP or a low abdominal leak-point pressure (VLPP), and it predicts poorer outcomes from support-only procedures.
Overactive bladder / urgency incontinence — pathophysiology
OAB is a symptom syndrome whose urodynamic correlate (when sought) is detrusor overactivity (DO) — involuntary detrusor contractions during the filling/storage phase. Proposed mechanisms:
- Myogenic — a detrusor prone to spontaneous, propagating contractions (partial denervation, increased electrical coupling between smooth-muscle cells).
- Neurogenic — loss of central inhibition or up-regulated reflexes: stroke, Parkinson's disease, multiple sclerosis, spinal cord disease.
- Urothelial/afferent — abnormal sensory signalling from the urothelium and suburothelium (the target of newer therapies).
Idiopathic OAB (no identifiable neurological cause) is much the commonest.
Other patterns to classify correctly
- Overflow — high PVR with dribbling; a failure to empty, not a storage problem (see urinary-retention).
- Continuous leakage — think vesicovaginal/ureterovaginal fistula (especially after pelvic surgery, caesarean, or obstructed labour) or an ectopic ureter (see gynaecological-fistulas).
- Functional incontinence — a continent lower tract but impaired mobility/cognition preventing timely toileting (important in the frail elderly).
Risk factors
Vaginal delivery and increasing parity, advancing age, menopause/oestrogen deficiency, obesity, chronic cough, constipation and chronic straining, prior pelvic surgery or radiotherapy, neurological disease, smoking, and family/connective-tissue predisposition.
Assessment
Figure C2.2 — Classifying the leak: history + ICIQ, the 3-day bladder diary, cough stress test, when urodynamics is needed, and the red flags (haematuria, continuous leak = fistula, overflow).
History
- Classify the symptom: leakage on effort (stress) vs leakage with urgency (urge) vs both; quantify frequency, nocturia, urgency, voided and leaked volumes, pad number/weight, and the triggers.
- Fluid and bladder irritants (caffeine, alcohol, total intake), bowel habit, obstetric and surgical history, prolapse and neurological symptoms, and the impact on quality of life (validated questionnaires such as ICIQ).
- A 3-day bladder diary is the single most useful tool — volumes, frequency, intake, leak episodes and their triggers — and often classifies the incontinence on its own.
Examination
- Abdominal (palpable bladder, masses) and pelvic examination — prolapse (POP-Q; see genital-prolapse), genitourinary atrophy, pelvic-floor muscle contraction (Oxford grading), and an observed cough stress test with a comfortably full bladder.
- Neurological examination if a neurogenic cause is suspected; BMI.
Investigations
- Urinalysis ± MSU — exclude infection; investigate haematuria (visible or persistent non-visible) on an urgent suspected-cancer pathway before ascribing symptoms to OAB.
- Post-void residual (bladder scan) — exclude incomplete emptying/overflow.
- Bladder diary as above.
- Urodynamic studies — not required before conservative management of straightforward SUI or OAB, but indicated before surgery, and where the picture is mixed, complex, neurogenic, or after previous incontinence surgery. Components: filling cystometry (detects detrusor overactivity, measures compliance and capacity), urethral function (MUCP, leak-point pressures for ISD), and pressure-flow voiding studies (distinguish obstruction from detrusor underactivity).
Management
Figure C2.3 — The stepped, conservative-first management ladder, separated by leak type: stress UI (PFMT → colposuspension/autologous fascial sling, with the mesh pause) vs OAB/urgency (bladder training → antimuscarinic/mirabegron → botulinum toxin/PTNS/sacral neuromodulation).
The approach is stepped and conservative-first (NICE NG123).
Shared first steps (all types)
Lifestyle: weight loss if BMI raised, moderate caffeine reduction, sensible fluid management (neither excessive nor over-restricted), treat constipation, stop smoking, and review diuretic timing. Vaginal (local) oestrogen for genitourinary atrophy (see climacteric-and-menopause).
Stress urinary incontinence
- First-line: supervised pelvic-floor muscle training (PFMT) for at least 3 months (a programme of at least 8 contractions three times daily), with biofeedback where available — effective and always tried before surgery.
- Surgery for persistent, bothersome SUI. Because of the national pause on vaginal mesh tape (synthetic mid-urethral slings), the first-line surgical options are now the native-tissue / autologous procedures: colposuspension (Burch) and the autologous rectus-fascial sling; both have strong long-term data. Urethral bulking agents are a less invasive, lower-durability option (useful in ISD or frailty). A synthetic mid-urethral sling is offered only within the restricted, fully-counselled pathway where it remains available.
- Duloxetine (an SNRI that increases pudendal/urethral tone) is an option when surgery is declined or unsuitable — second-line, limited by nausea and discontinuation.
Overactive bladder / urgency incontinence
- First-line: bladder training for at least 6 weeks (timed voiding with progressively lengthened intervals), often combined with PFMT and lifestyle measures.
- Pharmacotherapy if bladder training is insufficient:
- Antimuscarinics (solifenacin, tolterodine, darifenacin, fesoterodine, trospium). Avoid immediate-release oxybutynin in frail older women because of anticholinergic cognitive effects, and minimise total anticholinergic burden (linked to dementia risk with cumulative exposure).
- Mirabegron (a β3-adrenoceptor agonist) — relaxes the detrusor during storage; preferred where anticholinergic load is a concern; monitor blood pressure.
- Second-line specialist therapies (after specialist referral): intradetrusor botulinum toxin A (counsel re transient self-catheterisation), percutaneous tibial nerve stimulation (PTNS), and sacral neuromodulation; augmentation cystoplasty is a rare last resort.
Mixed incontinence
Treat the predominant/most bothersome component first, and reassess — treating one component can change the balance of the other.
Red flags / pitfalls
- Visible or persistent non-visible haematuria — refer urgently to exclude urinary tract malignancy before treating "OAB".
- Continuous leakage — suspect a fistula (gynaecological-fistulas) or ectopic ureter, not simple incontinence, particularly after pelvic surgery, caesarean, or obstructed labour.
- Incomplete emptying / palpable bladder — overflow from retention (urinary-retention); antimuscarinics here are harmful.
- Operating on SUI without urodynamics in mixed/complex/recurrent cases — risks worsening or unmasking the urgency component.
- High anticholinergic burden in older women — cognitive harm; favour mirabegron or non-drug options.
- Missing coexisting prolapse — it frequently accompanies and modifies incontinence, and can mask SUI (genital-prolapse).
- Counselling failures around mesh — women must understand the mesh pause and the native-tissue alternatives, and the history that produced the restriction.
- New urgency with neurological signs — consider a neurogenic bladder and image/refer accordingly.
Evidence anchors
- NICE NG123 — Urinary incontinence and pelvic organ prolapse in women: management (2019, last reviewed March 2025) — classification, conservative-first ladder, drug therapy, and the surgical pathway under the mesh restriction.
- Independent Medicines and Medical Devices Safety Review ("First Do No Harm", Cumberlege 2020) — basis of the vaginal-mesh pause for SUI and prolapse.
- ICS / IUGA standardised terminology of female lower urinary tract symptoms and urodynamics.
- NICE NG23 — Menopause — vaginal oestrogen for genitourinary syndrome of menopause.
- South African EML / NDoH Standard Treatment Guidelines — antimuscarinic and mirabegron availability.